AKT1 and malignant colon neoplasm: Importantly, the PI3K/mTOR inhibitor NVP-BEZ235 effectively reversed 5-FU resistance through inactivation of PI3K/Akt, which led to enhanced levels of FOXO3 in colon cancer cells 78.